Premium
(+)‐Cyanidanol‐3 in the Treatment of Acute Viral Hepatitis: A Randomized Controlled Trial
Author(s) -
Schomerus Hans,
Wiedmann Karl H.,
Dölle Wolfgang,
Peerenboom Herrmann,
Strohmeyer Georg,
Balzer Klaus,
Goebell Harald,
Dürr Hans K.,
Bode Christian,
Blum André L.,
Frösner Gert,
Gerlich Wolfram,
Berg Peter A.,
Dietz Klaus
Publication year - 1984
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840040226
Subject(s) - medicine , randomized controlled trial , viral hepatitis , virology , intensive care medicine , gastroenterology
One‐hundred sixty patients (81 cyanidanol, 79 placebo) were included in a double‐blind placebo‐controlled clinical trial to evaluate the effect of 3 gm (+)‐cyanidanol‐3 per day for 8 weeks on the clinical course of acute viral hepatitis and HBsAg elimination. Quantitative determination of HBsAg was performed at frequent intervals. The mean time for serum bilirubin to decrease to 1.3 mg per dl was 30.8 ± 3.5 days in the treated group and 52.2 ± 9.8 days in the control group, (p < 0.025). The time for SGOT to decrease to 100 IU per liter was 17.98 ± 1.82 in the treated group and 26.53 ± 3.7 in the control group (p < 0.025). No significant difference in the evolution of other laboratory values or symptoms was found. The elimination rate of HBsAg was identical in both groups. Treatment did not alter the incidence of chronicity.